Weaving is a resourceful technology which offers a large selection of solutions that are readily adaptable for tissue engineering (TE) of artificial heart valves (HV). The different ways that the yarns are interlaced in this technique could be used to produce complex architectures, such as the three-layer architecture of the leaflets. Once the assembly is complete, growth of cells in the scaffold would occur in the orientation of the yarn, enabling the deposition of extra cellular matrixes proteins in an oriented manner. Weaving technology is a rapidly evolving field that, first, needs to be understood, and then explored by tissue engineers, so that it could be used to create efficient scaffolds. Similarly, the textile engineers need to gain a basic understanding of key structural and mechanical aspects of the heart valve. The aim of this review is to provide the platform for joining these two fields and to enable cooperative research efforts. Moreover, examples of woven medical products and patents as well as related publication are discussed in this review, nevertheless due to the large, and continuously growing volume of data, only the aspects strictly associated with HVTE lay in the scope of this paper.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biotechadv.2017.07.012DOI Listing

Publication Analysis

Top Keywords

heart valve
8
tissue engineering
8
weaving heart
4
valve tissue
4
engineering weaving
4
weaving resourceful
4
resourceful technology
4
technology offers
4
offers large
4
large selection
4

Similar Publications

Background: Perimembranous ventricular septal defect (VSD) can be classified as having trabecular, inlet, or outlet extension. The surgical approach used in patch closure depends on the which valve of the tricuspid valve to suture around and the avoidance of the specialized conducting system. This retrospective study evaluated the usefulness of the "En face view" method for classifying perimembranous VSD.

View Article and Find Full Text PDF

One-year hemodynamic and clinical outcomes in self-expanding valves: Comparison of ACURATE neo2 versus ACURATE neo.

Cardiovasc Revasc Med

December 2024

Department of Cardiology and Catheterization Laboratories, Shonan Kamakura General Hospital, Okamoto 1370-1, Kamakura City, Kanagawa 247-8533, Japan. Electronic address:

Background/purpose: Transcatheter aortic valve replacement (TAVR) with ACURATE neo2 showed better hemodynamic outcomes by mitigating paravalvular leakage (PVL) compared with ACURATE neo, and revealed promising one-year outcomes in single-arm studies. However, studies comparing the hemodynamic and clinical outcomes of the two valves are still scarce. Therefore, this study aimed to compare the one-year hemodynamic and clinical outcomes between the neo2 and neo.

View Article and Find Full Text PDF

Background: Previous studies report that Hashimoto's thyroiditis (HT) may be associated with non-ischemic cardiomyopathy (NICM); However, the causal relationship remains to be elucidated. Here, we aimed to investigate the causal relationship between HT and NICM through Mendelian randomization (MR) and explore the potential mediating role of inflammatory cytokines within this association.

Methods: The bidirectional two-sample MR, multivariable MR and mediation MR analyses were conducted based on genome-wide association study summary datasets, and MR results were further supported by multiple sensitivity analysis methods.

View Article and Find Full Text PDF

Is connective tissue disorder a risk factor for durability after valve-sparing root replacement?

Semin Thorac Cardiovasc Surg

December 2024

Aortic Center, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH. Electronic address:

View Article and Find Full Text PDF

Echocardiographic Changes in Dogs with Stage B2 Myxomatous Mitral Valve Disease Treated with Pimobendan Monotherapy.

Vet Sci

November 2024

Department of Small Animal Clinical Science, School of Veterinary Science, University of Liverpool, Cardiology Service, Small Animal Teaching Hospital, Chester High Road, Neston CH64 7TE, UK.

The present study aimed to evaluate the effects of chronic pimobendan monotherapy on cardiac size in dogs with stage B2 myxomatous mitral valve disease (MMVD). Data from 31 dogs diagnosed with MMVD and cardiomegaly (LA/Ao ≥ 1.6 and LVIDdn ≥ 1.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!